Karyopharm Therapeutics (KPTI)
(Delayed Data from NSDQ)
$0.74 USD
0.00 (-0.15%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $0.73 -0.01 (-1.08%) 7:58 PM ET
2-Buy of 5 2
F Value D Growth C Momentum F VGM
Brokerage Reports
Karyopharm Therapeutics Inc. [KPTI]
Reports for Purchase
Showing records 41 - 60 ( 390 total )
Company: Karyopharm Therapeutics Inc.
Industry: Medical - Drugs
XPOVIO Sales at Low End of Guidance; Can Earlier Line MM Lift Growth?
Provider: Wedbush Securities Inc.
Analyst: NIERENGARTEN D
Company: Karyopharm Therapeutics Inc.
Industry: Medical - Drugs
Biotechnology- ASH Day 3 Roundup For Covered Companies
Provider: Wedbush Securities Inc.
Analyst: NIERENGARTEN D
Company: Karyopharm Therapeutics Inc.
Industry: Medical - Drugs
Updated Phase 1 Data for Xpovio in Treatment-Naive Patients Presented at ASH
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Karyopharm Therapeutics Inc.
Industry: Medical - Drugs
Company: Karyopharm Therapeutics Inc.
Industry: Medical - Drugs
Company: Karyopharm Therapeutics Inc.
Industry: Medical - Drugs
Company: Karyopharm Therapeutics Inc.
Industry: Medical - Drugs
Company: Karyopharm Therapeutics Inc.
Industry: Medical - Drugs
3Q22 Results; Xpovio Beats Our Estimate; Impressive Myelofibrosis Data in ASH Abstract
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Karyopharm Therapeutics Inc.
Industry: Medical - Drugs
Nexpovio Granted Orphan Medicinal Product Designation For the Treatment of Myelofibrosis From the European Commission
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Karyopharm Therapeutics Inc.
Industry: Medical - Drugs
Company: Karyopharm Therapeutics Inc.
Industry: Medical - Drugs
Company: Karyopharm Therapeutics Inc.
Industry: Medical - Drugs
Weekly Retail Sales Tracker for Hem. Malignancies - Week Ended August 19.
Provider: Wedbush Securities Inc.
Analyst: NIERENGARTEN D
Company: Karyopharm Therapeutics Inc.
Industry: Medical - Drugs
Company: Karyopharm Therapeutics Inc.
Industry: Medical - Drugs
Company: Karyopharm Therapeutics Inc.
Industry: Medical - Drugs
2Q22 Results; Xpovio Sales Increase as Treatment Shifts to Earlier Lines; Lowering PT to $18
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Karyopharm Therapeutics Inc.
Industry: Medical - Drugs
European Commission Grants Full Marketing For Nexpovio in MM Patients After at Least One Prior Therapy
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E